Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159490482> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2159490482 endingPage "1195" @default.
- W2159490482 startingPage "1179" @default.
- W2159490482 abstract "The most important change in the treatment of advanced breast cancer that will emerge over the next 10 years is the shift from adjuvant tamoxifen to adjuvant aromatase inhibitors. This will mean an increasing proportion of tamoxifen-naive aromatase inhibitor-resistant breast cancer. Research of the most appropriate methods of optimizing remaining endocrine sensitivity in these patients is needed. The rapid expansion in the understanding of the molecular basis of breast cancer biology provides potential targets for novel therapies. Despite these pivotal developments, resistance to endocrine therapy remains a key limitation in the management of advanced breast cancer. Until recently, the only option following the development of resistance to an endocrine agent was to change endocrine therapy and, on exhaustion of endocrine sensitivity, to move to cytotoxic chemotherapy. Understanding of at least some of the mechanisms underlying the development of endocrine resistance is now emerging. We now have the tools that may allow us to both overcome resistance and restore sensitivity, or to pre-empt certain types of resistance from developing. These tools include the increasing array of signal transduction inhibitors in combination with standard endocrine agents. Correct clinical management strategy can be guided by preclinical modeling but can only be validated by carefully designed clinical trials. These will, at the very least, need to be conducted with correlative translational research elements that will track changes in tumors as resistance emerges and will allow us to select the most appropriate treatment strategy for individual patients. Amongst the myriad of promising drugs there will undoubtedly be some that fail to meet current hopes, but we can be optimistic that a handful will find a useful place in keeping advanced breast cancer at bay for longer than can be achieved at present. However, the holy grail of a cure is likely, in the medium term, to remain elusively at the end of the rainbow for most of these patients. Several other methods for the management of these patients are in development. These include strategies to overcome endocrine resistance and methods to target deregulated endocrine and growth factor signaling pathways using gene and immunotherapy approaches." @default.
- W2159490482 created "2016-06-24" @default.
- W2159490482 creator A5025272654 @default.
- W2159490482 creator A5035931540 @default.
- W2159490482 creator A5038448622 @default.
- W2159490482 creator A5066136782 @default.
- W2159490482 date "2004-12-01" @default.
- W2159490482 modified "2023-09-23" @default.
- W2159490482 title "Endocrine therapy and other targeted therapies for metastatic breast cancer" @default.
- W2159490482 cites W1839333839 @default.
- W2159490482 cites W1848530042 @default.
- W2159490482 cites W1922595793 @default.
- W2159490482 cites W1934173384 @default.
- W2159490482 cites W1971296225 @default.
- W2159490482 cites W1995662976 @default.
- W2159490482 cites W2009983407 @default.
- W2159490482 cites W2057092446 @default.
- W2159490482 cites W2085481633 @default.
- W2159490482 cites W2085511718 @default.
- W2159490482 cites W2096840197 @default.
- W2159490482 cites W2139726760 @default.
- W2159490482 cites W2144209351 @default.
- W2159490482 cites W2148945481 @default.
- W2159490482 cites W2161550802 @default.
- W2159490482 cites W2202169216 @default.
- W2159490482 cites W2329229680 @default.
- W2159490482 doi "https://doi.org/10.1586/14737140.4.6.1179" @default.
- W2159490482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15606341" @default.
- W2159490482 hasPublicationYear "2004" @default.
- W2159490482 type Work @default.
- W2159490482 sameAs 2159490482 @default.
- W2159490482 citedByCount "11" @default.
- W2159490482 countsByYear W21594904822015 @default.
- W2159490482 countsByYear W21594904822016 @default.
- W2159490482 countsByYear W21594904822017 @default.
- W2159490482 countsByYear W21594904822022 @default.
- W2159490482 countsByYear W21594904822023 @default.
- W2159490482 crossrefType "journal-article" @default.
- W2159490482 hasAuthorship W2159490482A5025272654 @default.
- W2159490482 hasAuthorship W2159490482A5035931540 @default.
- W2159490482 hasAuthorship W2159490482A5038448622 @default.
- W2159490482 hasAuthorship W2159490482A5066136782 @default.
- W2159490482 hasConcept C121608353 @default.
- W2159490482 hasConcept C126322002 @default.
- W2159490482 hasConcept C128544194 @default.
- W2159490482 hasConcept C142724271 @default.
- W2159490482 hasConcept C143998085 @default.
- W2159490482 hasConcept C2776166826 @default.
- W2159490482 hasConcept C2777176818 @default.
- W2159490482 hasConcept C2777863537 @default.
- W2159490482 hasConcept C2778504769 @default.
- W2159490482 hasConcept C2781230642 @default.
- W2159490482 hasConcept C46699223 @default.
- W2159490482 hasConcept C530470458 @default.
- W2159490482 hasConcept C535046627 @default.
- W2159490482 hasConcept C60644358 @default.
- W2159490482 hasConcept C71315377 @default.
- W2159490482 hasConcept C71924100 @default.
- W2159490482 hasConcept C86803240 @default.
- W2159490482 hasConceptScore W2159490482C121608353 @default.
- W2159490482 hasConceptScore W2159490482C126322002 @default.
- W2159490482 hasConceptScore W2159490482C128544194 @default.
- W2159490482 hasConceptScore W2159490482C142724271 @default.
- W2159490482 hasConceptScore W2159490482C143998085 @default.
- W2159490482 hasConceptScore W2159490482C2776166826 @default.
- W2159490482 hasConceptScore W2159490482C2777176818 @default.
- W2159490482 hasConceptScore W2159490482C2777863537 @default.
- W2159490482 hasConceptScore W2159490482C2778504769 @default.
- W2159490482 hasConceptScore W2159490482C2781230642 @default.
- W2159490482 hasConceptScore W2159490482C46699223 @default.
- W2159490482 hasConceptScore W2159490482C530470458 @default.
- W2159490482 hasConceptScore W2159490482C535046627 @default.
- W2159490482 hasConceptScore W2159490482C60644358 @default.
- W2159490482 hasConceptScore W2159490482C71315377 @default.
- W2159490482 hasConceptScore W2159490482C71924100 @default.
- W2159490482 hasConceptScore W2159490482C86803240 @default.
- W2159490482 hasIssue "6" @default.
- W2159490482 hasLocation W21594904821 @default.
- W2159490482 hasLocation W21594904822 @default.
- W2159490482 hasOpenAccess W2159490482 @default.
- W2159490482 hasPrimaryLocation W21594904821 @default.
- W2159490482 hasRelatedWork W114669610 @default.
- W2159490482 hasRelatedWork W1843876547 @default.
- W2159490482 hasRelatedWork W2023271196 @default.
- W2159490482 hasRelatedWork W2040234260 @default.
- W2159490482 hasRelatedWork W2090746354 @default.
- W2159490482 hasRelatedWork W2134586533 @default.
- W2159490482 hasRelatedWork W2147084561 @default.
- W2159490482 hasRelatedWork W2148796794 @default.
- W2159490482 hasRelatedWork W2359357627 @default.
- W2159490482 hasRelatedWork W2589371209 @default.
- W2159490482 hasVolume "4" @default.
- W2159490482 isParatext "false" @default.
- W2159490482 isRetracted "false" @default.
- W2159490482 magId "2159490482" @default.
- W2159490482 workType "article" @default.